Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacokinetics and Safety of Ertapenem in the Postpartum Period

This study has been terminated.
(study terminated due to low subject accrual)
Information provided by (Responsible Party):
Daniel Benjamin, Duke University Medical Center Identifier:
First received: April 5, 2012
Last updated: May 19, 2015
Last verified: May 2015
The investigators are doing this study to learn more about the dosing and safety of ertapenem in women with suspected serious infections less than 42 days from the delivery of their infant.

Condition Intervention Phase
Drug: Ertapenem
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pharmacokinetics and Safety of Ertapenem in the Postpartum Period

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • Measure fraction of total and unbound Ertapenem. [ Time Frame: 2 years ]
    The fraction of unbound drug will be calculated using total and unbound drug concentrations. The appropriate non-compartmental pharmacokinetic parameters will be computed, including AUC24, AUCss, Cmax, CL, Vss, t1/2. PK parameters will be summarized by study cohort and compared using standard statistical methodology.

Secondary Outcome Measures:
  • Correlation between plasma drug concentrations and safety outcomes [ Time Frame: 2 years ]
    Adverse events (AE) thought to be related (definitely and probably) to study drug and all serious adverse events (SAE) will be recorded. The investigator will provide date of onset and resolution, intensity, frequency, action(s) taken, changes in study drug dosing and outcome.The safety review will include all SAEs, all AEs thought to be possibly or probably related to the study drug, and all patients who discontinued participation in the study early.

Enrollment: 3
Study Start Date: March 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ertapenem
Women diagnosed with postpartum endometritis
Drug: Ertapenem
Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
Other Name: Invanz

Detailed Description:
Ertapenem has received FDA approval for the indication of acute pelvic infection, though there is no pharmacokinetic data to guide dosing of ertapenem in postpartum women. The physiologic changes of the postpartum period make it likely that this special population requires dosing modification to achieve desired therapeutic targets. The objective of this study is to obtain a detailed knowledge of the pharmacokinetics of ertapenem during the postpartum period that will result in improved guidelines on maternal dosing and neonatal exposure. This is a prospective, open-label, single center, pharmacokinetic study of ertapenem in women diagnosed with postpartum endometritis. Subjects will include up to 24 women receiving treatment for a diagnosis of postpartum endometritis with ertapenem in the Duke University Hospital Labor & Delivery Unit. Each patient will participate in the study for approximately 7 days, though the total study duration is expected to be approximately 12 months. Descriptive statistics for the subjects will be calculated. The appropriate non-compartmental pharmacokinetic parameters will be computed, including AUC24, AUCss, Cmax, CL, Vss, t1/2. All subjects who receive one dose of study drug will be followed for safety, with planned internal review of safety data following the completion of 12 patients. Nursing infants of study subjects will also be followed for safety due to the potential for exposure to study drug through breastmilk.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older at the time of enrollment.
  • Postpartum period < 42 days at the time of enrollment.
  • Sufficient venous access to permit administration of study medication.
  • 2 clinical signs of postpartum endometritis:

    • Oral body temperature of > 101oF at any time, or a temperature of 100.4 on two occasions 6 hours apart.
    • Maternal tachycardia that parallels the temperature.
    • Uterine tenderness
    • Purulent vaginal discharge
  • Findings of advanced endometritis: dynamic ileus, pelvic peritonitis, pelvic abscess, bowel obstruction, necrosis of the lower uterine segment.

Exclusion Criteria:

  • History of previous hypersensitivity reactions to beta lactams.
  • Receiving valproic acid or divalproex sodium.
  • Creatinine clearance < 30 mL/min as calculated by the Cockroft-Gault equation.
  • Subject with a medical condition that, in the opinion of the investigator, would interfere with the pharmacokinetic evaluation of the medication, place the subject at an unacceptable risk of injury, or render the subject unable to meet the requirements of the protocol.
  • Previous participation in the study.
  • Exposure to ertapenem in the week prior to the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01587495

United States, North Carolina
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Daniel Benjamin
Principal Investigator: Geeta Swamy, MD Duke University
  More Information

Responsible Party: Daniel Benjamin, Professor, Duke University Medical Center Identifier: NCT01587495     History of Changes
Other Study ID Numbers: Pro00030565
Study First Received: April 5, 2012
Last Updated: May 19, 2015

Additional relevant MeSH terms:
Pelvic Inflammatory Disease
Adnexal Diseases
Genital Diseases, Female
Uterine Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on April 24, 2017